PubMed Health. A service of the National Library of Medicine, National Institutes of Health.
A.D.A.M. Medical Encyclopedia [Internet]. Atlanta (GA): A.D.A.M.; 2013.
A.D.A.M. Medical Encyclopedia.
Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency is a hereditary condition in which red blood cells break down when the body is exposed to certain drugs or the stress of infection.
Causes, incidence, and risk factors
G6PD deficiency occurs when a person is missing or doesn't have enough of an enzyme called glucose-6-phosphate dehydrogenase, which helps red blood cells work properly.
Too little G6PD leads to the destruction of red blood cells. This process is called hemolysis. When this process is actively occurring, it is called a hemolytic episode. The episodes are usually brief, because the body continues to produce new red blood cells, which have normal activity.
Red blood cell destruction can be triggered by infections, severe stress, certain foods (such as fava beans), and certain drugs, including:
- Antimalarial drugs
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
- Quinine
- Sulfa drugs
Other chemicals, such as those in mothballs, can also trigger an episode.
In the United States, G6PD deficiency is more common among blacks than whites. Men are more likely to have this disorder than women.
You are more likely to develop this condition if you:
- Are African American
- Are of Middle Eastern decent, particularly Kurdish or Sephardic Jewish
- Are male
- Have a family history of the deficiency
A form of this disorder is common in whites of Mediterranean descent. This form is also associated with acute episodes of hemolysis. Episodes are longer and more severe than in the other types of the disorder.
Symptoms
Persons with this condition do not display any signs of the disease until their red blood cells are exposed to certain chemicals in food or medicine, or to stress.
Symptoms are more common in men and may include:
- Fatigue
- Yellow skin color (jaundice)
Signs and tests
A blood test can be done to check the level of G6PD. See: G6PD screen
Other tests that may be done include:
- Complete blood count, including red blood cell count
- Hemoglobin - blood
Treatment
Treatment may involve:
- Medicines to treat an infection, if present
- Stopping any drugs that are causing red blood cell destruction
- Transfusions, in some cases
Expectations (prognosis)
Spontaneous recovery from a hemolytic episode is the usual outcome.
Complications
Rarely, kidney failure or death may occur following a severe hemolytic event.
Calling your health care provider
Call for an appointment with your health care provider if you have symptoms of this condition.
Call your health care provider if you have been diagnosed with G6PD deficiency and symptoms do not disappear after treatment.
Prevention
Persons with G6PD deficiency must strictly avoid things that can trigger an episode. Talk to your health care provider about your medications.
Genetic counseling or testing may be available to those who have a family history of the condition.
References
- Gregg XT, Prchal JT. Red blood cell enzymopathies. In: Hoffman R, Benz Jr. EJ, Shattil SJ, et al., eds. Hematology: Basic Principles and Practice. 5th ed. Philadelphia, Pa: Churchill Livingston; 2008:chap 45.
- Golan DER. Hemolytic anemias: red cell membrane and metabolic defects. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007:chap 165.
Review Date: 3/28/2010.
Reviewed by: David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; and James R. Mason, MD, Oncologist, Director, Blood and Marrow Transplantation Program and Stem Cell Processing Lab, Scripps Clinic, Torrey Pines, California. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only — they do not constitute endorsementscof those other sites. © 1997–2011 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
Should people treated for malaria caused by P. falciparum infection take a single dose of primaquine along with primary treatment?
Drugs that cure malaria caused by P. falciparum infection do not necessarily directly affect the gametocyte, which is the stage of the parasite that infects mosquitoes to complete the transmission cycle. Primaquine (PQ), a drug with antimalarial properties, does not cure P. falciparum infection but does kill P. falciparum gametocytes. Because of this property, this drug has long been recommended as a single dose or short course add‐on to P. falciparum infection treatment regimens. It is now recommended by the World Health Organization (WHO) and several national malaria control programs, with the intention of reducing community level malaria transmission. However, this drug also has potentially serious side effects in people with glucose‐6‐phosphate dehydrogenase (G6PD) deficiency, a common genetic variant. When they take this drug it may cause haemolysis (disintegration of red blood cells) which can be serious. This review examines the evidence of benefits and harms of PQ from trials where it has been used as an additional treatment intended to prevent malaria transmission.
The science behind screening testsScreening tests can lead to benefits and harms. Understand why, and how researchers find out if benefits outweigh harms for a test.
- Glucose-6-phosphate dehydrogenase deficiencyGlucose-6-phosphate dehydrogenase deficiencyPubMed Health
Your browsing activity is empty.
Activity recording is turned off.
See more...